Literature DB >> 18618062

Preparing for an influenza pandemic in Singapore.

Jeffery Cutter1.   

Abstract

The national strategy against pandemic influenza essentially consists of 3 prongs: (i) effective surveillance, (ii) mitigation of the pandemic's impact, and (iii) render the population immune through vaccination. When the pandemic hits Singapore, the response plan aims to achieve the following 3 outcomes: (i) maintenance of essential services to limit social and economic disruption, (ii) reduction of morbidity and mortality through antiviral treatment, and (iii) slow and limit the spread of influenza to reduce the surge on healthcare services. The biggest challenge will come from managing the surge of demand on healthcare services. A high level of preparedness will help healthcare services better cope with the surge.

Mesh:

Substances:

Year:  2008        PMID: 18618062

Source DB:  PubMed          Journal:  Ann Acad Med Singap        ISSN: 0304-4602            Impact factor:   2.473


  4 in total

1.  Early experience with influenza A H1N109 in an Australian intensive care unit.

Authors:  Tim Leen; Teresa A Williams; Lorraine Campbell; Jenny Chamberlain; Andree Gould; Geraldine McEntaggart; Gavin D Leslie
Journal:  Intensive Crit Care Nurs       Date:  2010-08       Impact factor: 3.072

2.  Nurses' perceptions of risk from emerging respiratory infectious diseases: a Singapore study.

Authors:  Yiwen Koh; Desley Hegney; Vicki Drury
Journal:  Int J Nurs Pract       Date:  2012-04       Impact factor: 2.066

3.  The Singapore field epidemiology service: insights into outbreak management.

Authors:  Peng-Lim Ooi; Theresa Seetoh; Jeffery Cutter
Journal:  J Prev Med Public Health       Date:  2012-09-28

Review 4.  Planning and coordination of the radiological response to the coronavirus disease 2019 (COVID-19) pandemic: the Singapore experience.

Authors:  I Y Y Tsou; C J Y Liew; B P Tan; H Chou; S B S Wong; K S H Loke; R C W Quah; A G S Tan; K H Tay
Journal:  Clin Radiol       Date:  2020-04-11       Impact factor: 2.350

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.